ICOS Corporation Company Profile

16:07 EDT 20th September 2017 | BioPortfolio

ICOS Corporation is developing proprietary biopharmaceuticals and small molecule pharmaceuticals for thetreatment of inflammatory diseases and other serious medical conditions. The Company's fundamental strategy is to identify and develop a significant number of potential product candidates into breakthrough products with high commercial potential. By understanding the underlying biochemical and physiological mechanisms and identifying the cellular and molecular entities involved in the disease process, ICOS is developing biopharmaceutical products that address important opportunities in the treatment of chronic and acute diseases that have inflammatory components as well as certain cardiovascular diseases and cancer. Through this strategy, the Company believes it will be able to develop novel therapeutics that are more selective and efficacious than current therapeutics.


22021 20th Avenue SouthEast
United States of America


Phone: 425 485 1900
Fax: 425 489 0356

News Articles [75 Associated News Articles listed on BioPortfolio]

Jounce reports safety data for ICOS agonist mAb JTX-2011

ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s

Intrinsic4D Inc. Announces Public Sale of Substantially all of the Assets of its Operating Subsidiary and Transfer to NEX

TORONTO, ONTARIO -- (Marketwired) -- 05/11/17 -- Intrinsic4D Inc. (the "Corporation") (TSX VENTURE: IFD) provides stakeholders with an update in relation to its financial status and solvency. Publi...

Savaria Announces Resignation of Director and Appointment of New Director

LAVAL, QUEBEC -- (Marketwired) -- 07/07/17 -- Savaria Corporation (TSX: SIS) ("Savaria" or the "Corporation"), one of North America's leaders in the accessibility industry, is pleased to announce th...

Ventripoint Announces Results of Annual Shareholders' Meeting and Grant of Options and DSUs

TORONTO, ONTARIO -- (Marketwired) -- 08/16/17 -- Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation") (TSX VENTURE: VPT) announces that at its Annual General Meeting on August 14, 2017 ...

TFH-derived dopamine accelerates productive synapses in germinal centres

Human follicular helper T cells engaging in synaptic interactions with germinal centre B cells release dopamine stored in chromogranin B+ granules, causing rapid externalization of ICOS ligand, which ...

CombiMatrix Corporation Reports First Quarter 2017 Financial and Operating Results

Achieves record reproductive health revenues on higher test volumes and average revenue per test, expands gross margin, significantly narrows operating loss and reports record cash collections Af...

Geron Corporation Reports First Quarter 2017 Financial Results and Recent Events

MENLO PARK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the first quarter ended March 31, 2017 and recent events. First Quarter...

PubMed Articles [16 Associated PubMed Articles listed on BioPortfolio]

KLRG1 expression identifies short-lived Foxp3(+) Treg effector cells with functional plasticity in islets of NOD mice.

A progressive waning in Foxp3(+) regulatory T (Treg) cell function provokes autoimmunity in the non-obese diabetic (NOD) mouse model of type 1 diabetes (T1D), a cellular defect rescued by prophylactic...

The strength of BCR signaling shapes terminal development of follicular helper T cells in mice.

Antibody production is key for effective immune response and relies on follicular helper T (Tfh) cells. B cell-Tfh cell interactions result either in an extra-follicular low affinity B-cell response o...

The TLR4-TRIF pathway can protect against the development of experimental allergic asthma.

The Toll-like Receptor (TLR) adaptor proteins Myeloid Differentiating Factor 88 (MyD88) and Toll, interleukin-1 Receptor and Resistance protein (TIR) domain-containing adaptor inducing interferon-β (...

Abatacept attenuates T follicular helper-cell-dependent B-cell hyperactivity in primary Sjögren's syndrome.

Objective To assess the effect of abatacept (CTLA-4-Ig), which limits T-cell activation, on homeostasis of CD4(+) T-cell subsets and T-cell-dependent B-cell hyperactivity in patients with primary Sjö...

β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity.

ICOS costimulation generates Th17 cells with durable memory responses to tumor. Herein, we found that ICOS induces PI3K/p110δ/Akt and Wnt/β-catenin pathways in Th17 cells. Coinhibiting PI3Kδ and β...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Prevention of Anthracycline-induced Cardiotoxicity

Anthracycline based anti-tumoral therapies are know to develop cardiac damage that could also lead to heart failure. Monocentric studies proved that a treatment with ACE inhibitors (ACEi) ...

Companies [173 Associated Companies listed on BioPortfolio]

ICOS Corporation

ICOS Corporation is developing proprietary biopharmaceuticals and small molecule pharmaceuticals for thetreatment of inflammatory diseases and other serious medical conditions. The Company's fundament...

Toshiba Corporation

Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultr...

Bruker Daltonics

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analy...

NEC Corporation of America

NEC Corporation of America (NEC) is a leading technology integrator providing solutions that improve the way people work and communicate. NEC delivers integrated Solutions for Soc...

Scale Computing

Scale Computing is a developer and manufacturer of complete, end-to-end intelligent storage solutions for SMEs. The entire Scale portfolio is based on its uniquely flexible Intell...

More Information about "ICOS Corporation" on BioPortfolio

We have published hundreds of ICOS Corporation news stories on BioPortfolio along with dozens of ICOS Corporation Clinical Trials and PubMed Articles about ICOS Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ICOS Corporation Companies in our database. You can also find out about relevant ICOS Corporation Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Corporate Database Quicklinks

Searches Linking to this Company Record